Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
The purpose of this study is to assess the microbiological cure rate of doripenem in the
 treatment of patients with complicated urinary tract infection or pyelonephritis. The study
 will also characterize the safety and tolerability of treatment with doripenem in patients
 with complicated urinary tract infection or pyelonephritis.
Doripenem is an antibiotic medication not yet approved by the US FDA. This is a phase 3,
 multi-center, prospective, open-label, single-arm study of doripenem in the treatment of
 complicated lower urinary tract infection or pyelonephritis in adults. Patients are
 hospitalized, but subsequently, patients may treated as outpatient or through home-based
 therapy at the discretion of the investigators. Conventional laboratory data will be
 collected from patients at specified times throughout the study. The primary endpoint is
 microbiological response measured at test of cure visit. The patients will receive doripenem
 with duration of therapy up to 10 days.
Inclusion Criteria:

 -  Diagnosis of complicated lower urinary tract infection or pyelonephritis

 Exclusion Criteria:

 -  Women who are pregnant, nursing or of child-bearing potential and not using a
 medically accepted, effective method of birth control

 -  History of moderate or severe hypersensitivity reactions to antibiotic medications